Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;180(3):361-70.
doi: 10.1111/cei.12605. Epub 2015 Apr 23.

The complex pathophysiology of acquired aplastic anaemia

Affiliations
Review

The complex pathophysiology of acquired aplastic anaemia

Y Zeng et al. Clin Exp Immunol. 2015 Jun.

Abstract

Immune-mediated destruction of haematopoietic stem/progenitor cells (HSPCs) plays a central role in the pathophysiology of acquired aplastic anaemia (aAA). Dysregulated CD8(+) cytotoxic T cells, CD4(+) T cells including T helper type 1 (Th1), Th2, regulatory T cells and Th17 cells, natural killer (NK) cells and NK T cells, along with the abnormal production of cytokines including interferon (IFN)-γ, tumour necrosis factor (TNF)-α and transforming growth factor (TGF)-β, induce apoptosis of HSPCs, constituting a consistent and defining feature of severe aAA. Alterations in the polymorphisms of TGF-β, IFN-γ and TNF-α genes, as well as certain human leucocyte antigen (HLA) alleles, may account for the propensity to immune-mediated killing of HSPCs and/or ineffective haematopoiesis. Although the inciting autoantigens remain elusive, autoantibodies are often detected in the serum. In addition, recent studies provide genetic and molecular evidence that intrinsic and/or secondary deficits in HSPCs and bone marrow mesenchymal stem cells may underlie the development of bone marrow failure.

Keywords: aplastic anemia; bone marrow mesenchymal stem cell; hematopoietic stem/progenitor cell, immune dysregulation.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Immune-mediated destruction of haematopoietic stem/progenitor cells. Following exposure to environmental insults, patients with acquired aplastic anaemia (aAA) develop aberrant immune responses that include oligoclonal expansion of T cells and abnormal production of myelosuppressive cytokines, including interferon (IFN)-γ and tumour necrosis factor (TNF)-α, leading to apoptosis of haematopoietic stem/progenitor cells (HSPCs). Deficient regulatory T cells (Treg), natural killer (NK) cells and mesenchymal stem cells (MSC) fail to suppress the dysregulated immune responses. Intrinsic deficits in HSPCs contribute further to the development of bone marrow failure. *Conflicting data exist.

References

    1. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120:1185–96. - PMC - PubMed
    1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–19. - PMC - PubMed
    1. Passweg JR, Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling? Haematologica. 2009;94:310–2. - PMC - PubMed
    1. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84:4257–61. - PubMed
    1. Dhaliwal JS, Wong L, Kamaluddin MA, et al. Susceptibility to aplastic anemia is associated with HLA-DRB1*1501 in an aboriginal population in Sabah, Malaysia. Hum Immunol. 2011;72:889–92. - PubMed